INO
Inovio Pharmaceuticals, Inc.
Nasdaq · usd
Inovio Pharmaceuticals, Inc. (INO) trades at $1.76 (+2.92%) as of 7:59:56 PM EST on Nov 20, 2026, +109.80% over the past month. Market cap is $329.66M, with 1.8 days to cover in short interest.
Stock performance
How Inovio Pharmaceuticals, Inc. (INO) stock has performed from one day to one year, with its 52-week range.
- 1D
- +2.92%
- 1W
- +23.08%
- 1M
- +109.80%
- YTD
- +1.15%
- 1Y
- -2.76%
- 52-wk range
- $0.56 – $2.72
Key statistics
Today's trading snapshot for INO: day range, open, previous close, volume and market cap.
- Day range
- $1.62 – $1.78
- Open
- $1.73
- Prev close
- $1.71
- Volume
- 7.92M
- Market cap
- $329.66M
- Shares out
- 110.18M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Inovio Pharmaceuticals, Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 1102.91
- P/B
- -9.72
- P/FCF
- —
- ROE
- 209.7%
- ROA
- -118.3%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 20, 2026
8-K filings
Material corporate events Inovio Pharmaceuticals, Inc. has disclosed to the SEC on Form 8-K.
- Director appointmentNov 17, 2026
Effective November 13, 2026, the Board of Directors (the "Board") of Inovio Pharmaceuticals, Inc. (the "Company") increased the size of the Board from eight to nine directors and appointed Jeffrey Libson to fill the newly created directorship. Mr. Libson will hold office until the Company's 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or his earlier death, resignation or removal.
- Quarterly earningsNov 10, 2026
On November 10, 2026, Inovio Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter and nine months ended September 30, 2026.
- Underwriting agreementNov 9, 2026
On November 5, 2026, Inovio Pharmaceuticals, Inc. entered into an underwriting agreement with Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters, relating to the issuance and sale by the Company in a public offering.
- Product or service launchNov 2, 2026
VOCERYQ was approved in combination with CELLECTRA® 5PSP, the Company's proprietary DNA medicine delivery device. The Company expects to make VOCERYQ available to order and ship in approximately 60 days and anticipates full field deployment during the first quarter of 2027.
- Bylaw amendmentOct 6, 2026
On October 6, 2026, the Board of Directors (the "Board") of Inovio Pharmaceuticals, Inc. (the "Company") approved and adopted an amendment (the "Bylaws Amendment") to the Amended and Restated Bylaws of the Company, effective immediately. The Bylaws Amendment adds a new Article 12 (Exclusive Forum), which provides that, unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for certain specified actions... In addition, the Bylaws Amendment provides that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.
Dividend history and stock splits
Inovio Pharmaceuticals, Inc.'s recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-12Jan 25, 2024
- 1-for-4Jun 6, 2014
INO short interest
How heavily INO is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 1.8
- Short interest
- 22.1M
- Avg volume
- 12.15M
As of · reported to FINRA twice monthly.
INO news
The latest news and headlines about Inovio Pharmaceuticals, Inc. (INO).
- PGEN Q3 Earnings Call Highlights Launch Momentum and CompetitionpositiveZacks Investment Research· Nov 9, 2026
- Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?negativeZacks Investment Research· Nov 2, 2026
- FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast CancerpositiveZacks Investment Research· Oct 8, 2026
- PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?positiveZacks Investment Research· Sep 30, 2026
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape CarepositiveGlobeNewswire Inc.· Sep 30, 2026
Frequently asked questions
What is the Inovio Pharmaceuticals, Inc. (INO) stock price today?
Inovio Pharmaceuticals, Inc. (INO) is trading at $1.76 (+2.92% on the day) as of 7:59:56 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Inovio Pharmaceuticals, Inc.?
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases.
What is the short interest in INO?
As of Oct 30, 2026, INO has 22.1M shares short and 1.8 days to cover.
What exchange is INO listed on?
Inovio Pharmaceuticals, Inc. (INO) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of INO with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a INO analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.